KRAS and juvenile myelomonocytic leukemia: Activating mutations of NRAS and KRAS were also noted in a recently described pathological entity called ﻿RAS-associated autoimmune leukoproliferative disorder (RALD), which shares overlapping features with JMML and ALPS [32–34].